Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3797690
Max Phase: Preclinical
Molecular Formula: C48H69N13O11
Molecular Weight: 1004.16
Molecule Type: Small molecule
Associated Items:
ID: ALA3797690
Max Phase: Preclinical
Molecular Formula: C48H69N13O11
Molecular Weight: 1004.16
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O
Standard InChI: InChI=1S/C48H69N13O11/c1-32(62)58-41(26-35-28-52-31-57-35)47(68)60-39(24-33-10-3-2-4-11-33)46(67)59-38(14-7-15-55-48(50)51)45(66)61-40(25-34-27-56-37-13-6-5-12-36(34)37)44(65)54-17-9-19-70-21-23-71-22-20-69-18-8-16-53-43(64)30-72-29-42(49)63/h2-6,10-13,27-28,31,38-41,56H,7-9,14-26,29-30H2,1H3,(H2,49,63)(H,52,57)(H,53,64)(H,54,65)(H,58,62)(H,59,67)(H,60,68)(H,61,66)(H4,50,51,55)/t38-,39+,40-,41-/m0/s1
Standard InChI Key: UBCQDVLHVQEUPW-XRFUAQTBSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1004.16 | Molecular Weight (Monoisotopic): 1003.5240 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Lensing CJ, Freeman KT, Schnell SM, Adank DN, Speth RC, Haskell-Luevano C.. (2016) An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers., 59 (7): [PMID:26959173] [10.1021/acs.jmedchem.5b01894] |
2. Lensing CJ, Freeman KT, Schnell SM, Speth RC, Zarth AT, Haskell-Luevano C.. (2018) Developing a Biased Unmatched Bivalent Ligand (BUmBL) Design Strategy to Target the GPCR Homodimer Allosteric Signaling (cAMP over β-Arrestin 2 Recruitment) Within the Melanocortin Receptors., 62 (1): [PMID:29669202] [10.1021/acs.jmedchem.8b00238] |
Source(1):